Sarepta Therapeutics, Inc. (SRPT): Total Assets
$3.35B
As of 2025-12-31
$3.19B
As of 2026-06-30
+2.3%
3-year compound annual growth
+2.3%
5-year compound annual growth
+28.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.35B | -15.5% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $3.96B | +21.4% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $3.26B | +4.4% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $3.13B | -0.6% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $3.15B | +5.5% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $2.98B | +63.7% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $1.82B | +11.0% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $1.64B | +25.5% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $1.31B | +208.4% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $424.10M | +54.9% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $273.78M | -7.2% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $295.03M | +1.2% | 2016-02-25, Balance as of period end |
| 2013-12-31 | $291.57M | +42.2% | 2015-02-26, Balance as of period end |
| 2012-12-31 | $204.99M | +277.0% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $54.37M | +18.3% | 2013-03-15, Balance as of period end |
| 2010-12-31 | $45.98M | n/a | 2012-03-13, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $3.35B | -15.5% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $19.62B | +7.7% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $2.90B | +70.0% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $3.68B | +5.1% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $7.88B | +7.0% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.50B | +10.3% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $7.59B | +8.7% |
| Alkermes plc. (ALKS) | 2025-12-31 | $2.49B | +21.0% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $4.97B | +17.1% |
Compare SRPT, RPRX, PTCT, AMRX side by side · Screen every company in Pharmaceutical Preparations ↗